The reasons for these results include:
• Institutional investors strongly represent the industry
• The ACA’s 2.3 percent medical device excise tax
• Increased mergers and acquisition leading to increased financial leverage
• Main financial ratios look high
• Litigation-related charges and impairments impacted profitability
The top 10 companies are:
1. Boston Scientific
2. Medtronic plc
3. Abbott Laboratories
4. Edwards Lifesciences
5. Becton, Dickson and Company
6. C.R. Bard
7. St. Jude Medical
8 Baxter
9. Stryker
10 Zimmer Biomet
More articles on orthopedic devices:
5 observations on Amedica shares dropping by 15.92%
Global MIS market to grow to $50B+ by 2019: 7 key trends
ExactechGPS launches globally: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.